Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway

References

• Xia L, Song M, Sun M, Chen W, Yang C. miR-486 promotes Capan-2 pancreatic cancer cell proliferation by targeting phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Front Genet. 2019;10:541. doi:10.3389/fgene.2019.0054131258546
   PubMed Web of Science ®Google Scholar
• Li H, Zhang SR, Xu HX, et al. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. J Cancer. 2019;10(12):2670–2678. doi:10.7150/jca.3207231258775
   PubMed Web of Science ®Google Scholar
• Zhou Y, Cui J, Du H. Autoantibody-targeted TAAs in pancreatic cancer: a comprehensive analysis. Pancreatol. 2019;19(5):760–768.
   Web of Science ®Google Scholar
• Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer. Ann Oncol. 2019;28.doi:10.1093/annonc/mdz200
   Google Scholar
• Thomas NA, Abraham RG, Dedi B, Krucher NA. Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells. Int J Oncol. 2019;54(2):527–536.30535494
   PubMed Web of Science ®Google Scholar
• Ishimoto U, Kinoshita A. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Cancer Chemother Pharmacol. 2019; 84(3):647-654. doi:10.1007/s00280-019-03895-2
   Google Scholar
• Li Z, Wang M, Yao X, et al. Development of a novel EGFR-targeting antibody-drug conjugate for pancreatic cancer therapy. Target Oncol. 2019;14(1):93–105. doi:10.1007/s11523-018-0616-830635821
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12(1):63. doi:10.1186/s13045-019-0759-931227004
   PubMedGoogle Scholar
• Lee K, Kim Y, Jung HA, et al. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer. 2019;130:87–92. doi:10.1016/j.lungcan.2019.01.01230885357
   PubMed Web of Science ®Google Scholar
• Qiu W, Zhang C, Wang S, et al. A novel anti-EGFR mAb Ame55 with lower toxicity and better efficacy than cetuximab when combined with irinotecan. J Immunol Res. 2019;2019:3017360.
   Google Scholar
• Muhammad N, Steele R, Isbell TS, Philips N, Ray RB. Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget. 2017;8(39):66226–66236. doi:10.18632/oncotarget.1988729029506
   PubMedGoogle Scholar
• Bhattacharya S, Muhammad N, Steele R, Peng G, Ray RB. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth. Oncotarget. 2016;7(22):33202–33209. doi:10.18632/oncotarget.v7i2227120805
   PubMedGoogle Scholar
• Evans L, Ferguson B. Emodin attenuates pathological cardiac hypertrophy by regulating gene expression through acetyl-histone-mediated actions (P06-036-19). Current Dev Nutr. 2019;3(Suppl 1). doi:10.1093/cdn/nzz031.P06-036-19
   Google Scholar
• Li Y, Xiong W, Yang J, et al. Attenuation of inflammation by emodin in lipopolysaccharide-induced acute kidney injury via inhibition of toll-like receptor 2 signal pathway. Iran J Kidney Dis. 2015;9(3):202–208.25957424
   PubMed Web of Science ®Google Scholar
• Xie R, Liu M, Li S. Emodin weakens liver inflammatory injury triggered by lipopolysaccharide through elevating microRNA-145 in vitro and in vivo. Artif Cells Nanomed Biotechnol. 2019;47(1):1877–1887. doi:10.1080/21691401.2019.161401531079494
   PubMed Web of Science ®Google Scholar
• Braumann C, Koplin G. Dose-dependent role of novel agents emodin and BTB14431 in colonic cancer treatment in rats. Acta Chir Belg. 2017;117(6):376–384.
   Google Scholar
• Gao R, Wu X, Huang Z, et al. Anti-tumor effect of aloe-emodin on cervical cancer cells was associated with human papillomavirus E6/E7 and glucose metabolism. Onco Targets Ther. 2019;12:3713–3721. doi:10.2147/OTT.S18240531190872
   PubMed Web of Science ®Google Scholar
• Chen H, Wei W, Guo Y, et al. Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep. 2011;25(5):1253–1261.21305255
   PubMed Web of Science ®Google Scholar
• Ma JW, Hung CM, Lin YC, Ho CT, Kao JY, Way TD. Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget. 2016;7(37):58915–58930.27391337
   PubMedGoogle Scholar
• Chen KC, Juang SH, Lien JC. Identification of antiproliferative emodin analogues as inhibitors of epidermal growth factor receptor in cancer. Int J Mol Med. 2019;43(3):1281–1288.30664170
   PubMed Web of Science ®Google Scholar
• Saunders IT, Mir H, Kapur N, Singh S. Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways. Cancer Cell Int. 2019;19:98. doi:10.1186/s12935-019-0820-331011292
   PubMed Web of Science ®Google Scholar
• Lin SZ, Xu JB, Ji X, et al. Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-beta/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs. Mol Med Rep. 2015;12(4):5865–5871. doi:10.3892/mmr.2015.415826238071
   PubMed Web of Science ®Google Scholar
• Juan L, Peishu L, Hongluan M, Ancong W, Xiaolei Z. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep. 2009;21(6):1605–1610.19424643
   PubMed Web of Science ®Google Scholar
• Yang L, Lin S, Kang Y, et al. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J Exp Clin Cancer Res. 2019;38(1):31. doi:10.1186/s13046-018-1015-930674340
   PubMed Web of Science ®Google Scholar
• Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G. Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37(1):47–61. doi:10.1016/j.tips.2015.10.00126576830
   PubMed Web of Science ®Google Scholar
• Shi L, Zheng H, Hu W, et al. Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer. Onco Targets Ther. 2017;10:1767–1776. doi:10.2147/OTT.S12944928367059
   PubMed Web of Science ®Google Scholar
• Norum OJ, Asv F, Weyergang A, Golab J, Berg K. Photochemical delivery of bleomycin induces T-cell activation of importance for curative effect and systemic anti-tumor immunity. J Controlled Release Off J Controlled Release Soc. 2017;268:120–127. doi:10.1016/j.jconrel.2017.10.015
   PubMed Web of Science ®Google Scholar
• Man S, Gao W, Wei C, Liu C. Anticancer drugs from traditional toxic Chinese medicines. Phytother Res. 2012;26(10):1449–1465.22389143
   PubMed Web of Science ®Google Scholar
• Ii F. Anti-tumor natural product research focused on plants found in the Southern Appalachian region. [Theses]. Western Carolina University. 2010.
   Google Scholar
• Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol. 2006;72(8):941–948. doi:10.1016/j.bcp.2006.07.02216934227
   PubMed Web of Science ®Google Scholar
• Torres AF, Nogueira C, Magalhaes J, et al. Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution. Anal Cell Pathol Cell Oncol. 2014;2014:352925.
   PubMed Web of Science ®Google Scholar
• Mohammad N, Singh SV, Malvi P, et al. Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-beta-cyclodextrin: involvement of p53 and Fas receptor ligand complex. Sci Rep. 2015;5:11853. doi:10.1038/srep1185326149967
   PubMed Web of Science ®Google Scholar
• Guo J, Li W, Shi H, et al. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013;382(1–2):103–111. doi:10.1007/s11010-013-1723-623771315
   PubMed Web of Science ®Google Scholar
• Lihua H, Liwu F. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sinica B. 2015;5(5):390–401. doi:10.1016/j.apsb.2015.07.001
   PubMed Web of Science ®Google Scholar
• Zhang N, Zeng Y, Du W, et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol. 2016;49(4):1360. doi:10.3892/ijo.2016.363227499357
   PubMed Web of Science ®Google Scholar
• Ung N, Putoczki TL, Stylli SS, et al. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biol Ther. 2014;15(5):623–632. doi:10.4161/cbt.2817924556630
   PubMed Web of Science ®Google Scholar